About NXPE family member 3
NXPE family member 3 (NXPE3) is a protein
from Homo sapiens identified by UniProt accession
Q969Y0, 559 residues long.
MolForge cross-references it against 0 known binders and
21 disease associations.
Target properties
| Protein name | NXPE family member 3 |
| UniProt accession | Q969Y0 |
| Gene | NXPE3 |
| Organism | Homo sapiens |
| Length | 559 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (21)
Diseases linked to this target (Open Targets).
- COVID-19 · score 0.18
- psoriasis · score 0.18
- psoriasis vulgaris · score 0.14
- serum non-albumin protein measurement · score 0.14
- PHF-tau measurement · score 0.13
- type 2 diabetes mellitus · score 0.13
- peritonsillar abscess · score 0.10
- C-reactive protein measurement · score 0.04
- eosinophil count · score 0.04
- anxiety disorder · score 0.03
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q969Y0-F1 | alphafold | PREDICTED | 89.58 | — |
Amino-acid sequence (559 residues)
MWTNFFKLRL FCCLLAVLMV VVLVINVTQV EYLDHETVSA TFIDSSGQFV SSQVTGISRN PYCGYDQQTL SSQERMEEDS LLAALHRQVP DVGPVPFVKS TDPSSSYFVI LNSAAFFKVG SQLEVLVHVQ DFQRKPKKYG GDYLQARIHS LKLQAGAVGR VVDYQNGFYK VFFTLLWPGK VKVSVSLVHP SEGIRVLQRL QEDKPDRVYF KSLFRSGRIS ETTECNVCLP GNLPLCNFTD LYTGEPWFCF KPKKLPCSSR ITHFKGGYLK GLLTAAESAF FQSGVNIKMP VNSSGPDWVT VIPRRIKETN SLELSQGSGT FPSGYYYKDQ WRPRKFKMRQ FNDPDNITEC LQRKVVHLFG DSTIRQWFEY LTTFVPDLVE FNLGSPKNVG PFLAVDQKHN ILLKYRCHGP PIRFTTVFSN ELHYVANELN GIVGGKNTVV AIAVWSHFST FPLEVYIRRL RNIRRAVVRL LDRSPKTVVV IRTANAQELG PEVSLFNSDW YNFQLDTILR RMFSGVGVYL VDAWEMTLAH YLPHKLHPDE VIVKNQLDMF LSFVCPLET
Explore NXPE family member 3 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets